文献速递胰腺与胆道疾病

复发性急性胰腺炎的自然史:对干预试验设计的启示

Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design.
PubMed 文献 · Aliment Pharmacol Ther · 2026-06-25

这项丹麦全国性队列研究纳入45338例首次急性胰腺炎住院成人,随访中位4.5年,6894例发生复发性急性胰腺炎(RAP),风险15.2%(95%CI 14.9%-15.5%)。RAP复发风险随发作次数累积而升高,12个月累积复发率从1次RAP后的17%升至5次后的46%,且发作间期随次数增加而缩短。结论提示RAP呈加速病程,针对既往发作次数较多患者的富集风险试验设计可能提高干预研究可行性。

要点

  • 首次AP住院后RAP总体风险15.2%,中位随访4.5年。
  • RAP复发风险随既往发作次数增加而升高,12个月累积复发率从17%升至46%。
  • 多数复发在12个月内发生,发作间期随发作次数增加而缩短。

核心结论

  • 复发性急性胰腺炎呈加速病程,复发风险随发作次数增加而升高。
  • 针对既往发作次数较多患者的富集风险试验设计可能提高未来干预研究的可行性和统计效率。

研究设计与样本

  • 丹麦全国性队列研究,纳入2000年1月1日至2022年12月31日期间经国家健康登记系统识别的45338例首次急性胰腺炎住院成人。
  • RAP定义为间隔≥90天的急性胰腺炎再住院。
  • 采用竞争风险模型与伪观测估计RAP累积发病率,并按既往AP发作次数分层;采用Weibull模型估计发作间期。

主要发现

  • 中位随访4.5年期间,6894例患者发生RAP,风险为15.2%(95%CI 14.9%-15.5%)。
  • RAP复发风险随累积发作次数增加而升高。
  • 12个月RAP累积复发率从1次RAP发作后的17%升至5次发作后的46%。
  • 多数复发发生在12个月内,且发作间期随发作次数增加而缩短。
  • Weibull模型显示磨损模式,形状参数随连续RAP发作逐渐增大,提示复发风险随时间加速。

临床怎么用

  • 对复发性急性胰腺炎患者应关注12个月内早期复发风险,尤其是既往发作次数较多者。
  • 未来干预试验可考虑纳入既往发作次数较多的RAP患者以富集风险、提高统计效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with acute pancreatitis (AP) often experience recurrent acute pancreatitis (RAP), increasing the risk of chronic pancreatitis (CP) and long-term complications. Progression along the AP-RAP-CP spectrum has been explored in epidemiological studies, but available data provide limited insight into recurrence dynamics within RAP itself. This information is crucial for the design of studies aiming to prevent RAP recurrence and disease progression. METHODS: In this nationwide cohort study, we included 45,338 Danish adults hospitalised with an incident episode of AP between January 1, 2000, and December 31, 2022, identified through national health registries. RAP was defined as recurrent hospitalisations for AP separated by ≥ 90 days. Competing risk models with pseudo-observations estimated cumulative incidence functions for RAP recurrence stratified by the number of prior AP episodes. Inter-episode intervals were estimated using Weibull models. RESULTS: During a median follow-up of 4.5 years, 6894 patients developed RAP, corresponding to a 15.2% risk (95% confidence interval, 14.9%-15.5%). The RAP recurrence risk increased with accumulating episodes. The 12-month cumulative incidence of RAP recurrence rose from 17% after one RAP episode to 46% after five episodes. Most recurrences occurred within 12 months, and inter-episode intervals shortened with increasing episode number. Weibull models demonstrated a wear-out pattern, with shape parameters increasing progressively across successive RAP episodes, indicating accelerating recurrence risk over time. CONCLUSIONS: RAP follows an accelerating course characterised by increasing recurrence risk. Risk-enriched trial designs targeting patients with more prior episodes may improve the feasibility and statistical efficiency of future interventional studies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Olesen SS, Bruun NH, Davidsen L, et al. Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design. Aliment Pharmacol Ther. 2026. PMID: 42350924. doi:10.1111/apt.70820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。